Oberotatug ravtansine

雷坦欧罗妥塔单抗

Report date: 2024/02/21 12:32:39

Base Information

Drug NameOberotatug ravtansine
Drug Alias NameMEN-1309OBT-076MEN1309/OBT076
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin inhibitorsAnti-Lymphocyte antigen 75
TargetsLymphocyte antigen 75Tubulin
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsCarcinoma, Adenoid Cystic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOxford Biotherapeutics LtdMenarini
China Registration ClassN/A

Develop Information

Active CompaniesOxford Biotherapeutics Ltd
Inactive CompaniesMenarini GroupGroupe Oncologie Radiotherapie Tete Et Cou
Active IndicationsSolid tumours
Inactive IndicationsHead and Neck NeoplasmsCarcinoma, Adenoid CysticLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A